Active Targeting Shielding Lipids for Targeted LNP Delivery
Targeted LNP Shielding Lipids (PEG-Free) | CliCr® Conjugation | Curapath
Engineered PEG-free polysarcosine lipids modified with CliCr® conjugation technology to enable precise ligand attachment and extrahepatic LNP targeting.
Explore our Active Targeting Shielding Lipids catalog, a curated selection of PEG-free polysarcosine lipids engineered for precise ligand conjugation and extrahepatic LNP delivery.
Download now and discover CliCr®-modified shielding lipids designed to enhance functionalization density, maintain particle integrity, and enable targeted delivery to T cells, lung, brain, and beyond — available from R&D to GMP-ready scale.
What Makes These Shielding Lipids Different?
These next-generation shielding lipids combine Curapath’s PEG alternatives with CliCr® site-specific conjugation technology, enabling controlled functionalization of lipid nanoparticles (LNPs) without compromising particle integrity.
Unlike conventional PEGylated systems, these materials are designed to:
- Avoid PEG-related immunogenicity
- Enable higher functionalization density
- Maintain LNP size, PDI and encapsulation efficiency
- Support targeted delivery beyond the live
Designed for Extrahepatic and Cell-Specific Targeting
Our active targeting shielding lipids are optimized for:
- T cell targeting
- Lung delivery
- Brain delivery
- Extrahepatic biodistribution strategies
These materials are compatible with ligand conjugation approaches through the CliCr® platform, allowing attachment of antibodies, peptides, or other targeting moieties.
Advantages of Combining PEG Alternatives with CliCr® Technology
- Better safety profile (no PEG immunogenicity reactions)
- Higher % LNP functionalization degree Vs gold standards
- Comparable physicochemical profile to non-targeted LNPs
- Increased tissue selectivity
Frequently asked Questions
Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in lipid- and polymer-based delivery systems. We support biotech and pharmaceutical companies from early development through GMP-ready manufacturing.
Our core expertise includes polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer–drug conjugates, and coating polymers.
CliCr® is a site-specific conjugation platform that enables controlled attachment of targeting ligands to lipid and polymer nanoparticles while maintaining structural integrity.
Thanks to an strategic License agreement with Cristal therapeutics Curapath is the exclusive CDMO authorized to use the CliCr® platform for the targeted delivery of nucleic acids through polymer and lipid nanoparticles (LNPs)
To learn more about this agreement you can check the full press release
Yes. These shielding lipids are based on polysarcosine (PSar) platforms designed to avoid PEG-associated immunogenicity.
Most materials are available from 50 mg for R&D purposes, with scalable production options for larger preclinical and GMP manufacturing needs.
Selected materials are available with scalable GMP-ready processes depending on project requirements.
To place an order please indicate the product or products you are interested in as well as desired quantities here
Contact a Chemist Today
Contact Us, and we can discuss your specific therapeutic program and how Curapath can help build the right solution to advance your unique drug.